Leslie M. Shaw, PhD
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Director, Clinical Toxicology Laboratory
University of Pennsylvania Perelman School of Medicine
Contact InformationHospital of the University of Pennsylvania
7.103 Founders Pavilion
3400 Spruce Street
Philadelphia, PA 19104
Office: (215) 662-6575
Fax: (215) 662-7529
Email: Les.Shaw@uphs.upenn.edu; firstname.lastname@example.org
Development, validation and implementation of neurodegenerative diseases biomarkers in cerebrospinal fluid and plasma into treatment trials and clinical studies (eg, ADNI study; PPMI study). These studies include the use of manual and highly automated immunoassays and for amyloid beta(1-42) and for total tau the use of high sensitivity UPLC/tandem mass spectrometry. Multi-modal statistical analyses of these study data to address several questions including the diagnostic utilities of these biomarkers; assessments of the longitudinal trajectories of these biomarkers in AD, MCI and cognitively normal controls to assess the neuropathological changes over time in these individuals.
Measurement and interpretation of the toxicokinetics of drugs and toxins in patients affected by them. Interpretation of the pharmacokinetics of immunosuppressant maintenance medications in transplant patients.
Development and implementation of mass spectrometry-based methods for measuring small molecules of clinical utility including therapeutic drugs, toxins and special chemistry tests including 25-OH vitamin D.
B.S. (Cum Laude, Chemistry), LeMoyne College, Syracuse, New York, 1962
Ph.D. (Biochemistry), S.U.N.Y. at Upstate Medical Center, 1968
American Board of Clinical Chemistry, 1973
American Board of Clinical Chemistry in Toxicological Chemistry, 1990
USC School of Medicine, Laboratory of Applied Pharmacokinetics, 1995
NIH Post doctoral Fellowship Department of Molecular Biology, The Johns Hopkins University, Baltimore, MD, 1968-1970
Fellow, Neuroscience Research Program, 1969-1969
NIH Postdoctoral Fellowship, William Pepper Laboratories, Hospital of the University of Pennsylvania, Philadelphia, PA, 1970-1972
Awards and Honors
Norman Kubasik Lectureship Award, Upstate New York AACC Meeting, 1992-1992
Outstanding Speaker Award, 1995, 1996, 1997, 2000, 2001, 2002, 2003, American Association for Clinical Chemistry, 1995-2003
Reinhold Award, Philadelphia Section, AACC, 1995-1995
The Peter C Nowell Teaching Award, University of Pennsylvania Medical Center, 1999-1999
IATDMCT Charles Pippenger Award for Outstanding Contributions in Therapeutic Drug Monitoring, 1999-1999
The Kevin Salhany, MD, Award for Excellence in Clinical Teaching; Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, 2005-2005
LeMoyne College - Distinguished Alumni Award, 2012-2012
AACC Lifetime Achievement Award in Clinical Chemistry and Laboratory Medicine., 2013
Memberships and Professional Organizations
Philadelphia Section, American Association for Clinical Chemistry:, 1978 - Present
Philadelphia Section, American Association for Clinical Chemistry: 1996 (Program Chairman).
Philadelphia Section, American Association for Clinical Chemistry: 1978, 1978 - Present
AACC/NACB Task Force on Cyclosporine Monitoring, 1985 - Present
Therapeutic Drug Monitoring and Clinical Toxicology Division of the AACC:, 1991 - Present
USP Council of Experts,, 2001 - 2002
Alzheimers Association, 2005 - Present
Alzheimers Association Global Biomarker Standardization Consortium., 2011 - Present
Eli Lilly, 2011 - Present
International Federation of Clinical Chemistry, 2013 - present
International Federation on Clinical Chemistry, - Present
International Association for Therapeutic Drug Monitoring and Clinical Toxicology, - Present
American Chemical Society, - Present
American Association for the Advancement of Science, - Present
American Association for Clinical Chemistry, - Present
American Association of Pathologists, - Present
American Society for Clinical Pharmacology and Therapeutics:, - Present
National Academy of Clinical Biochemistry:, - Present
NCCLS Area Committee on Toxicology and Drug Monitoring, - Present
American Society for Mass Spectroscopy, - Present
Alpha Sigma Nu, National Jesuit Honor Society, - Present
Society of Toxicology, 2004 - Present, - Present
Active Cigarette smoking in cognitively-normal elders and probable Alzheimer's Disease is associated with Elevated Cerebrospinal fluid Oxidative Stress biomarkers.
Durazzo TC, Korecka M, Trojanowski JQ, Weiner MW, O'Hara R, Ashford JW, Shaw LM, Alzheimer's Disease Neuroimaging Initiative., J Alzheimers Dis., 2016, PMID:27472882
Assessing the commutability of reference material formats for the harmonization of amyloid-B measurements.
Bjerke M, Andreasson U, Kuhlman J, Portelius E, Pannee J, Lewczuk P, Umek RM, Vanmechelen E, Vanderstichele H, Stoops E, Lewis J, Vandijck M, Kostanjevecki V, Jeromin A, Salamone SJ, Schmidt O, Matzen A, Madin K, Eichenlaub U, Bittner T, Shaw LM, Zegers I, Zetterberg H, Blennow K., Clin Chem Lab Med. 54(7): , 2016, PMID:26495928
CSF Biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligorska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Kieburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, Shaw LM; Parkinson's Progression Marker Initiative., Acta Neuropathol. 131(6): 935-49, 2016, PMID:27021906
Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
Vilas D, Shaw LM, Taylor P, Berg D, Brockman K, Aasly J, Marras C, Pont-Sunyer C, Rios J, Marek K, Tolosa E., Mov Disord. 31(6): 906-14, 2016, PMID:27041685
Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease.
Podlesniy P, Vilas D, Taylor P, Shaw LM, Tolosa E, Trullas R., Neurobiol Dis. 94(): 10-17, 2016
Impact of frequent cerebrospinal fluid sampling on AB levels: systematic approach to elucidate influencing factors.
Van Broeck B, Timmers M, Ramael S, Bogert J, Shaw LM, Mercken M, Slemmon J, Van Nueten L, Engelborghs S, Streffer JR., Alzheimers Res Ther. 8(1): , 2016, PMID:27206648
Kuhlmann J, Andreasson U, Pannee J, Bjerke M, Portelius E, Leinerbach A, Bittner T, Korecka M, Jenkins RG, Vanderstichele H, Stoops E, Lewczuk P, Shaw LM, Zegers I, Schimmel H, Zetterberg H, Blennow K, IFCC Working Group on Standarization of CSF Proteins (WG-CSF)., Clin Chim Acta., 2016, PMID:27216941
Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging.
Abner EL, Jicha GA, Shaw LM, Trojanowski JQ, Goetzl EJ., Ann Clin Transl Neurol. 3(5): 399-403, 2016
The effect of Propofol Versus Isoflurane Anesthesia on Human Cerebrospinal fluid markers of Alzheimer's Disease: Results of a Randomized trial.
berger M, Nadler JW, Friedman A, McDonagh DL, Bennett ER, Cooter M, Qi W, Laskowitz DT, Ponnusamy V, Newman MF, Shaw LM, Warner DS, Matjew JP, James ML; MAD-PIA trial team., J Alzheimers Dis. 52(4): 1299-310, 2016
Round robin test on quantification of amyloid-B 1-42 in cerebrospinal fluid by mass spectrometry.
Pannee J, Gobom J, Shaw LM, Korecka M, Chambers EE, Lame M, Jenkins R, Mylott W, Carrillo MC, Zegers I, Zetterberg H, Blennow K, Portelius E., Alzheimer's & Dementia 12(1): 55-9, 2016